NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
16 trialsNCT02864147 2024-05-02
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Yale University
Phase 2 Completed
NCT03180684 2023-08-25
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Inovio Pharmaceuticals
Phase 2 Completed
NCT00189267 2022-02-07
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Viatris Inc.
Phase 2 Completed
NCT03233412 2021-02-17
Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
Barretos Cancer Hospital
Phase 2 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT00899574 2015-12-07
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
NYU Langone Health
Phase 2 Completed
NCT00941811 2015-06-16
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
Medical University of Vienna
Phase 2 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT01611480 2013-06-26
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Moberg Pharma AB
Phase 2 Completed
NCT00273910 2012-10-19
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00651703 2010-11-15
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
Phase 2 Completed
NCT00335179 2010-07-23
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00601016 2008-01-25
A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
St. Justine's Hospital
Phase 2 Completed